IREB2 and renal carcinoma: Herein, blocking the activation of ACO1 or IREB2 by its inhibitors OMA or SNP (39, 40) ameliorated sorafenib-triggered cell death, supporting that ACO1 and IREB2 could participate in its cytotoxic influence on renal cancer cells.